This website is optimized for visualization with Firefox and Internet Explorer (8 or 9)

CLINICAL DEVELOPMENT PIPELINE

Regulatory Review

  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase 3

Phase 2

  • BACE inhibitor Alzheimer's
    LY3202626 (BACE Inhibitor), a chemical entity, is an oral beta secretase cleaving enzyme (BACE) inhibitor. LY3202626 is being studied for the treatment of Alzheimer's disease.

    For more information on LY3202626 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase 1

  • Aß42 Antibody
    "Aß42 antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • D1 potentiator
    "D1 potentiator" is a new chemical entity being studied for the treatment of dementia.

     
  • N3pG-Aß Monoclonal Antibody
    "N3pG-Aß Monoclonal Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • N3pG-Ab Monoclonal Antibody
    "N3pG-Aß Monoclonal Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • Selective BACE 1 inh
    "Selective BACE 1 inhibitor" is a new chemical entity being studied for the treatment of Alzheimer's disease.

     
  • Tau Antibody
    "Tau Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Pipeline Disclaimer
The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently-approved products, that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued, delayed or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of July 21, 2017. Lilly assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.
  • Select NME
  • Select NILEX
  • Diagnostic
GTM-PQNKVL